- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Bolt Projects Holdings, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 27.02. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Bolt Projects to delist from Nasdaq, deregister with SEC | 3 | Seeking Alpha | ||
| 19.02. | Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration | 783 | Business Wire | BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (OTC Pink: BSLK, BSLKW), a developer of biomaterials for the beauty and personal care industry, today announced that its Board of Directors... ► Artikel lesen | |
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 985 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 17.07.25 | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | 1.149 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,910 | -9,06 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,652 | +3,19 % | Fate Therapeutics, Inc.: Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited... ► Artikel lesen | |
| TRINITY BIOTECH | 0,389 | -0,46 % | Trinity Biotech reports positive clinical findings for next-gen CGM | ||
| ARCTURUS THERAPEUTICS | 7,160 | -1,92 % | Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? | ||
| OVID THERAPEUTICS | 2,360 | -0,84 % | Ovid Therapeutics Inc.: Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development | Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting... ► Artikel lesen | |
| CABALETTA BIO | 3,115 | -0,48 % | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress | 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through... ► Artikel lesen | |
| LONGEVERON | 0,665 | +3,45 % | Longeveron Appoints Marie Washburn as Chief Financial Officer | Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating... ► Artikel lesen | |
| VOR BIOPHARMA | 19,750 | -2,76 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,57 | +0,24 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 19,180 | +1,64 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,750 | +5,71 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| VIRAX BIOLABS GROUP | 6,340 | +99,37 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | +1,25 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
Das Unternehmen BOLT PROJECTS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,583 Euro und damit -27,01 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOLT PROJECTS HOLDINGS INC finden Sie auf Wallstreet Online.